### Hari Koul, M.Sc., PhD, FACN, FASN

Associate Director
LSU LCMC Health Cancer Center

Professor
Department of Interdisciplinary Oncology
Departments of Urology and Biochemistry & Molecular Biology

Phone: (504) 568-3003 Fax: (504) 568-2093 Email: hkoul@lsuhsc.edu

1700 Tulane Ave. New Orleans, LA 70112

#### Education


B.Sc., Kashmir University (Srinagar-India), Biology and Chemistry - 1984 M.Sc., Kashmir University (Srinagar-India), Biochemistry - 1986

Ph.D, Postgraduate Institute of Medical Education and Research (Chandigarh-India) - 1990 University of Massachusetts Medical School, Postdoctoral Fellowship - 1991- 1993, Research Associate - 1993 - 1996

# What I'm Working On

Over the past three decades, Dr. Koul has greatly contributed to the understanding of molecular mechanisms, specifically signal transduction pathways in genitor-urinary disorders. Dr. Koul's research is focused on understanding the mechanisms of tumor progression and the emergence of therapeutic resistance.

## **Biography**



Dr. Hari K. Koul is associate director for cancer research training & education coordination for the LSU LCMC Health Cancer Center and professor at LSU Health New Orleans School of Medicine, departments of Interdisciplinary Oncology, Biochemistry and Molecular Biology and Urology. He also is head of the GU Oncology Research Program at LSU Health New Orleans.

He is internationally recognized as one of the leading translational researchers in urologic diseases. Over the past three decades, Dr. Koul has greatly contributed to the understanding of molecular mechanisms, specifically signal transduction pathways in genitor-urinary disorders. Dr. Koul's research is focused on understanding the mechanisms of tumor progression and the emergence of therapeutic

resistance, with special focus on epigenetic mechanisms and spatio-temporal regulation of gene expression; identification of novel markers that could potentially distinguish indolent vs.

aggressive prostate cancer; developing new small molecular inhibitors to overcome therapy resistance, and evaluation of the role of Prostate Derived Ets Transcription Factor in PCa Health Disparities.

Dr. Koul earned a bachelor's degree in biology and chemistry and master's degree in biochemistry from Kashmir University-Srinagar, India and holds a doctorate in biochemistry from PGI, Chandigarh, India. As a graduate student Dr. Koul was a recipient of national merit fellowships from CSIR-India. Dr. Koul received postdoctoral training (1991-1995) at the UMASS Medical School, Worcester, MA. He was promoted to Instructor at UMASS Medical School and continued to work there until 1996. Dr. Koul served as a senior staff scientist and founding member of the urology research team at Henry Ford Health Sciences Center, Detroit, MI from 1996-2003. Dr. Koul was recruited as professor and founding program director of urology research at the University of Colorado Denver, School of Medicine. In 2013, Dr. Koul was recruited to LSU Health New Orleans as a professor with tenure and Carroll W. Feist Endowed Chair in Cancer and Head of the Department of Biochemistry and Molecular Biology, School of Medicine, and associate director for Basic and Translational Research of the Feist Weiller Cancer Center at LSUHSC-Shreveport.

Dr. Koul is recognized for his scientific leadership and original contributions to molecular mechanisms in urologic diseases across the globe. He is a tireless advocate for scientific research enterprise and is a thought leader. In recognition for his scientific contributions, tireless service, and research leadership, Dr. Koul has been elected president of the Society of Basic Urology Research (2016-2017), president of the Research on Calculous Kinetics Society-USA (2005-2006), fellow of the American Society of Nephrology (2010), fellow of the American College of Nutrition (2004), foreign fellow of the Royal Society of Medicine (2020) and co-chair of the American Urological Association Research Grants Committee (2014-2015). He has served as a charter member of the American Urological Association Research Council (2007-2013; 2016-2018) and member-at-large/ board of directors of the Society of Basic Urological Research. He is a recipient of the Outstanding Achievement Award of the Society of American Asian Scientists in Cancer Research (2009). He served as a charter member of the NIH Study Section on the Urologic Kidney and Genitourinary Development (2003-2007) and US Veterans Administration Merit Review Subcommittee for Oncology (2004-2009). He also served as a member of the US Veterans Administration Merit Review Subcommittee for Surgery (2004-2008). He is frequently called to serve as a chair/member on several NIH and DOD panels for his expertise and leadership skills.

#### Research Interests

- Prostate cancer
- Urologic diseases

## **Previous Research**

<u>Severe COVID-19 is Characterized by an Impaired Type I Interferon Response and Elevated Levels of Arginase Producing Granulocytic Myeloid Derived Suppressor Cells</u>

July 14, 2021 Front Immunol

doi: 10.3389/fimmu.2021.695972

Hippo Pathway: Regulation, Deregulation and Potential Therapeutic Targets in Cancer

June 1, 2021 Cancer Lett

doi: 10.1016/j.canlet.2021.03.006

Prostate-Derived ETS Factor (PDEF) Modulates Yes Associated Protein 1 (YAP1) in Prostate Cancer Cells: A Potential Cross-Talk between PDEF and Hippo Signaling

December 10, 2019 Pharmaceuticals (Basel) doi: 10.3390/ph12040181

<u>Protocadherin 7 is Overexpressed in Castration Resistant Prostate Cancer and Promotes</u>
Aberrant MEK and AKT Signaling

November 2019

Prostate

doi: 10.1002/pros.23898

<u>Eukaryotic Translation Initiation Factor 4 Gamma 1 (EIF4G1): A Target For Cancer Therapeutic Intervention?</u>

August 31, 2019
Cancer Cell Int

doi: 10.1186/s12935-019-0947-2

View more